Drugs / Bovine Lactoferrin
Bovine Lactoferrin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04738058 | Dec 2020 → Dec 2021 | — | Mansoura University Children Hospital | Unknown | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05783180 | Jun 2023 | COVID-19 | Jose David Suarez, MD | Withdrawn | No outcome recorded |
| Phase 2 | NCT04526821 | Oct 2020 → Feb 2021 | COVID-19 | Universidad Peruana Cayetano Heredia | Terminated | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03431558 | May 2018 → May 2020 | necrotizing enterocolitis, neonatal sepsis | Aga Khan University | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bovine Lactoferrin | “Liposomal Bovine Lactoferrin (LbLf)” NCT05783180 ↗ |
| Known as | bLF | “This study aimed to determine the effect of bovine lactoferrin (bLF) in the prevention of SARS-CoV-2 infection in health care personnel.” PMID 36474100 ↗ Dec 2022 |
| Known as | LbLf | “Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Liposomal Bovine Lactoferrin (LbLf) and Liposomal Zn (LZn))” NCT05783180 ↗ |
| Known as | Sesderma LACTYFERRIN Forte | “Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Liposomal Bovine Lactoferrin (LbLf) and Liposomal Zn (LZn))” NCT05783180 ↗ |
| Action | Inhibit | “inhibiting the union of the SARS-CoV-2 spike protein with its receptor (ACE-II receptors)” NCT04526821 ↗ |
| Modality | Protein / enzyme biologic | “Lactoferrin is a natural product with broad-spectrum antimicrobial properties and glycoprotein that is actively involved in innate immune host responses.” PMID 33704071 ↗ Mar 2021 |
| Route | Oral | “2 different daily oral prophylactic doses of bovine lactoferrin (150 mg or 300 mg) and placebo” PMID 33704071 ↗ Mar 2021 |